Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: A phase III randomized study by the fondazione Italiana linfomi

Journal of Clinical Oncology

Volumn 31, Issue 27, 2013, Pages 3351-3359

  Vitolo, Umberto ^a   Ladetto, Marco ^a   Boccomini, Carola ^a   Botto, Barbara ^a   Chiappella, Annalisa ^a   Evangelista, Andrea ^a   Lobetti Bodoni, Chiara ^a   Ciccone, Giovannino ^a   Baldini, Luca ^b   De Angelis, Federico ^c   Tucci, Alessandra ^d   Rossi, Giuseppe ^d   Chiarenza, Annalisa ^e   Pinto, Antonello ^f   De Renzo, Amalia ^g   Zaja, Francesco ^h   Castellino, Claudia ⁱ   Bari, Alessia ^j   De Celis, Isabel Alvarez ^k   Parvis, Guido ^l   Gamba, Enrica ^m   more..

^a Cittadella Salute e della Scienza Hospital and University   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e Ferrarotto Hospital   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

ⁱ S CROCE E CARLE HOSPITAL   (Italy)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^k S MARIA NUOVA HOSPITAL   (Italy)

^l SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^m Roche   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; LEVOFLOXACIN; MITOXANTRONE; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL OBSERVATION; COMORBIDITY; CONFERENCE PAPER; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG FATALITY; EVALUATION STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEART DISEASE; HEPATITIS B VIRUS; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION PREVENTION; INFUSION RELATED REACTION; LUNG DISEASE; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STEVENS JOHNSON SYNDROME; TONSILLITIS; VIRUS REACTIVATION; AGE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; LYMPHOMA, FOLLICULAR; MIDDLE AGED; PATHOLOGY;

AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSOLIDATION CHEMOTHERAPY; DEXAMETHASONE; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MITOXANTRONE; VIDARABINE;

EID: 84890161836     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.8290     Document Type: Conference Paper

References (32)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997
2. Salles GA: Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program:216-225, 2007
3. Hainsworth JD, Litchy S, Burris HA 3rd, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
4. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
5. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
6. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824-4831, 2008
7. Schulz H, Bohlius JF, Trelle S, et al: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst 99:706-714, 2007
8. Ninan MJ, Morrison VA: Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient. Expert Rev Hematol 2:173-182, 2009
9. Thieblemont C, Coiffier B: Lymphoma in older patients. J Clin Oncol 25:1916-1923, 2007
10. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
11. Federico M, Bellei M, Marcheselli L, et al: Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555-4562, 2009
12. McLaughlin P, Hagemeister FB, Rodriguez MA, et al: Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27:37-41, 2000
13. Vitolo U, Boccomini C, Ladetto M, et al: High clinical and molecular response rate in elderly patients with advanced stage follicular lymphoma treated at diagnosis with a brief chemoimmunotherapy FND rituximab. Blood 100:11, 2002 (abstr 359a)
14. van Oers MH: Rituximab maintenance therapy: A step forward in follicular lymphoma. Haematologica 92:826-833, 2007
15. Forstpointner R, Unterhalt M, Dreyling M, et al: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108: 4003-4008, 2006
16. van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006
17. van Oers MH, Van Glabbeke M, Giurgea L, et al: Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Longterm outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28:2853-2858, 2010
18. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
19. Marzano A, Angelucci E, Andreone P, et al: Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39:397-408, 2007
20. Ladetto M, Sametti S, Donovan JW, et al: A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Exp Hematol 29:183-193, 2001
21. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
22. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases eventfree survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004
23. Vidal L, Gafter-Gvili A, Salles G, et al: Rituximab maintenance for the treatment of patients with follicular lymphoma: An updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 103:1799-1806, 2011
24. Hainsworth JD, Litchy S, Shaffer DW, et al: Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1088-1095, 2005
25. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
26. Taverna C, Bassi S, Hitz F, et al: First results of long-term rituximab maintenance treatment in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35/03. J Clin Oncol 27:442s, 2009 (suppl; abstr 8534)
27. Balducci L, Extermann M: Management of cancer in the older person: A practical approach. Oncologist 5:224-237, 2000
28. Hagemeister F, Cabanillas F, Coleman M, et al: The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist 10:150-159, 2005
29. Czuczman MS, Koryzna A, Mohr A, et al: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23:694-704, 2005
30. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
31. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
32. Rummel M, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 114:22, 2009 (abstr 405a)